LUTATHERA^® (lutetium [177Lu] oxodotreotide): Power Against Progression

The LUTATHERA^® brochure offers a succinct summary of the clinical evidence supporting the effectiveness and well-understood safety profile of LUTATHERA^® in the management of GEP-NETs in adults. It presents the key progression-free survival and objective response rate data for LUTATHERA^® and describes its impact on patient quality of life, as well as presenting its toxicity profile. It also provides a concise overview of recommended treatment regimen and the consensus guideline recommendations from the European Neuroendocrine Tumour Society (ENETS).